Developer docs
API playgroundTry for free, no card

Search company profiles

Modality.AI

Full company profile

uuid0000uah

Namestring
Modality.AI
Legal namestring
Modality.AI, Inc.
Websiteurl
modality.ai
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Modality.AI is a San Francisco-based health technology company founded in 2018 by David Suendermann-Oeft, PhD (CEO) and David Pautler, PhD (CTO) that has built an AI-powered multimodal conversational platform for objective clinical assessment of neurological and psychiatric conditions. The platform uses real-time audiovisual dialog with an AI virtual guide named "Tina" to capture and analyze a patient's speech, facial expressions, and motor function through standard webcam-equipped devices, generating explainable digital biomarkers in minutes without requiring a clinic visit, dedicated hardware, or a clinical rater. The system is listed with the FDA as a Class II medical device, operates on a HIPAA-compliant AI infrastructure, supports GDPR-compliant regional data residency, and is available in more than a dozen languages and dialects.

Short descriptiontext

Modality.AI is an FDA-listed, HIPAA-compliant AI platform that sells multimodal speech, facial, and motor digital biomarkers to pharmaceutical and biotech sponsors for decentralized clinical trials in neurological and psychiatric conditions.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical trial assessments, digital biomarkers, conversational AI platform, neurological disease monitoring, speech video analytics
Industry1 code
PRIMARYHDAAAFAC
Conversational AI Platforms (chat/voice bots, orchestration)
NAICS code1 code
  • Computer Systems Design and Related Services54151
SIC code1 code
  • Services-Prepackaged Software7372
Product category
Clinical Trial Digital Biomarker Software
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Clinical Trial Assessment Platform (SaaS)
TypeSubscription Recurring
Description

Modality provides its multimodal assessment platform to pharma and biotech sponsors for use in regulated clinical trials, supporting both in-clinic and remote administration. The platform supplements or replaces rater-based assessments. Revenue is generated through platform access fees charged to clinical trial sponsors. The company reports commercial traction with an expanding interventional pipeline across ALS, schizophrenia, ADHD, muscular dystrophy, and postoperative neurocognitive disorders.

modality.ai
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 record
1Tina
Description

Modality's virtual guide named Tina that leads structured conversations with patients to standardize assessment across sites and languages, reduce site burden, and enable effective decentralized trials.

modality.ai
Core offering1 text field

Modality.AI provides an AI-powered multimodal assessment platform that uses real-time audiovisual dialog with a virtual guide named Tina to objectively evaluate speech, facial expression, and motor function in patients with neurological and psychiatric conditions. The platform enables both in-clinic and remote administration of clinical trial assessments, allowing pharma and biotech sponsors to supplement or replace rater-based endpoints with automated digital biomarkers. Data is processed in real time on a HIPAA-compliant AI platform, producing explainable, auditable results, and the platform is listed with the FDA as a Class II medical device.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Digital speech endpoints were sensitive to short-term disease progression in a Phase 1b ALS trial (VRG50635), detecting functional decline during the 8-week pretreatment run-in period
+4 more records
Product overview1 text field

Modality.AI offers a unified AI-powered multimodal assessment platform consisting of the Modality Platform and its virtual guide Tina. The platform integrates speech analytics, facial expression analysis via computer vision, and motor function assessment into a single session, enabling remote or in-clinic assessment of neurological and psychiatric conditions without requiring clinic visits, dedicated devices, or clinical raters. Data is processed by a secure, HIPAA-compliant AI platform in real-time with results that are explainable and auditable. The platform is listed with the FDA as a Class II medical device.

Product and service1 record
1The Modality Platform
Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-07-17
Description

Strategic partnership combining Modality's sensitive speech/visual measures with Ametris's continuous real-world function data from wearable sensors. The goal is to sharpen signal detection in challenging neuro trials by enabling sponsors to better assess whether a therapy is demonstrating measurable efficacy. Joint webinars and co-presentations at ADDS (Ametris Digital Data Summit). Ametris rebranded from ActiGraph in 2025.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-07-17
Description

Modality provided speech endpoint assessments for Verge Genomics' VRG50635 Phase 1b ALS clinical trial, demonstrating that digital speech endpoints tracked disease progression and aligned with standard clinical outcomes including ALSFRS-R, respiratory function, and neurofilament biomarkers. Results published in Nature Scientific Reports.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Target ALS and Modality.AI collaborate in a multimodal study of ALS, leveraging the Modality Platform for remote audiovisual assessments in the Target ALS Global Natural History Study (14 people with ALS). Joint presentations at Target ALS Annual Meeting and multiple co-authored publications.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Modality partners with EverythingALS on the Speech Project, generating the largest longitudinal audiovisual dataset of people with ALS (143 pALS). Collaborative research presentations and co-authored publications advancing ALS speech biomarker science.

5Precision ALS
Strategic tierMinorTypeStrategic or Co-development Partner
Description

European collaboration for ALS research and clinical trials, with Modality participating in Precision ALS meetings and events in Europe.

modality.ai
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Long-standing collaboration on speech and visual assessments for schizophrenia, resulting in 17+ peer-reviewed publications. Collaborators include Dr. Jean-Pierre Lindenmayer (Director of the Manhattan Schizophrenia Research Program at NKI).

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaboration with Valis Bioscience on CNS clinical research, with joint presence at the ASCP Annual Meeting. Valis Bioscience co-founders include Christian Yavorsky.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

NIH awarded a $2.3 million grant to Modality.AI and the MGH Institute of Health Professions to validate if app-collected data is as effective as expert clinical observations for ALS diagnosis.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

IBM Staff Research Scientist Kely Norel presented on deep learning models for assessing speech intelligibility in ALS, building on data collected through EverythingALS's Speech Project in collaboration with Modality.AI.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Digital cognitive assessment platform combining AR-based motor and cognitive tasks with AI for early detection of neurological conditions. Adjacent in digital neuro assessment but more consumer/clinical than pharma-trial focused.

TypeBroad incumbent
Description

Major eClinical platform serving pharma/biotech with Rave EDC, eCOA, and trial technology infrastructure. Potential incumbent competitor or partner if it expands native digital endpoint / biomarker capabilities.

TypeDirect peer
Description

Develops and validates digital endpoints from wearable sensor data for use in regulatory-grade clinical trials. Comparable positioning as a regulated digital endpoint provider for pharma.

TypeBroad incumbent
Description

Large clinical trial technology vendor offering eCOA, imaging, respiratory, and digital endpoint solutions to pharma sponsors. Broader portfolio than Modality, but overlaps in regulated digital endpoints for clinical trials.

TypeDirect peer
Description

EEG-based digital biomarker platform for CNS clinical trials, including neurodegenerative and psychiatric indications. Overlaps with Modality on the goal of replacing subjective clinical scales with objective, regulated digital measures.

TypeDirect peer
Description

Voice biomarker platform analyzing short voice samples for mental and respiratory health monitoring. Comparable AI-on-speech approach for health-condition detection, though more consumer- and primary-care oriented.

TypeDirect peer
Description

Speech analytics platform that extracts clinical-grade speech biomarkers for neurological conditions. Direct competitor in the speech-as-biomarker niche for pharma trials.

TypeDirect peer
Description

Provides digital cognitive and speech-based assessments for CNS clinical trials across indications including Alzheimer's, Parkinson's, and schizophrenia. Closely comparable to Modality in deploying validated digital endpoints for pharma-sponsored studies.

TypeDirect peer
Description

Digital cognitive testing company supplying computerized assessments (including speech/voice elements) to clinical trials across CNS indications. Comparable go-to-market selling objective digital endpoints into pharma trials.

TypeDirect peer
Description

Digital biomarker company deploying wearable and remote sensor data as clinical trial endpoints in CNS, respiratory, and other indications. Overlaps with Modality on objective, decentralized trial endpoints for pharma sponsors.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights8 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers8 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability7 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles16 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors16 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Modality.AI

Clinical Trial Digital Biomarker Softwaremodality.ai

Modality.AI is an FDA-listed, HIPAA-compliant AI platform that sells multimodal speech, facial, and motor digital biomarkers to pharmaceutical and biotech sponsors for decentralized clinical trials in neurological and psychiatric conditions.

What Modality.AI does

Modality.AI is a San Francisco-based health technology company founded in 2018 by David Suendermann-Oeft, PhD (CEO) and David Pautler, PhD (CTO) that has built an AI-powered multimodal conversational platform for objective clinical assessment of neurological and psychiatric conditions. The platform uses real-time audiovisual dialog with an AI virtual guide named "Tina" to capture and analyze a patient's speech, facial expressions, and motor function through standard webcam-equipped devices, generating explainable digital biomarkers in minutes without requiring a clinic visit, dedicated hardware, or a clinical rater. The system is listed with the FDA as a Class II medical device, operates on a HIPAA-compliant AI infrastructure, supports GDPR-compliant regional data residency, and is available in more than a dozen languages and dialects.

Modality.AI firmographics

Firmographics
Name
Modality.AI
Legal name
Modality.AI, Inc.
Website
https://modality.ai
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Short description
Modality.AI is an FDA-listed, HIPAA-compliant AI platform that sells multimodal speech, facial, and motor digital biomarkers to pharmaceutical and biotech sponsors for decentralized clinical trials in neurological and psychiatric conditions.
Ownership category
akta.pro rank

Modality.AI industry classification

Industry
Product category
Clinical Trial Digital Biomarker Software
NAICS
Computer Systems Design and Related Services (54151)
SIC
Services-Prepackaged Software (7372)
akta.pro industry
PRIMARYHDAAAFAC
Conversational AI Platforms (chat/voice bots, orchestration)

Keywords

  • Clinical trial assessments
  • Digital biomarkers
  • Conversational AI platform
  • Neurological disease monitoring
  • Speech video analytics

Where Modality.AI is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Modality.AI business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. Clinical Trial Assessment Platform (SaaS): Modality provides its multimodal assessment platform to pharma and biotech sponsors for use in regulated clinical trials, supporting both in-clinic and remote administration. The platform supplements or replaces rater-based assessments. Revenue is generated through platform access fees charged to clinical trial sponsors. The company reports commercial traction with an expanding interventional pipeline across ALS, schizophrenia, ADHD, muscular dystrophy, and postoperative neurocognitive disorders.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels8 records

Modality.AI product offering

Product offering

Core offering

Modality.AI provides an AI-powered multimodal assessment platform that uses real-time audiovisual dialog with a virtual guide named Tina to objectively evaluate speech, facial expression, and motor function in patients with neurological and psychiatric conditions. The platform enables both in-clinic and remote administration of clinical trial assessments, allowing pharma and biotech sponsors to supplement or replace rater-based endpoints with automated digital biomarkers. Data is processed in real time on a HIPAA-compliant AI platform, producing explainable, auditable results, and the platform is listed with the FDA as a Class II medical device.

Product overview

Modality.AI offers a unified AI-powered multimodal assessment platform consisting of the Modality Platform and its virtual guide Tina. The platform integrates speech analytics, facial expression analysis via computer vision, and motor function assessment into a single session, enabling remote or in-clinic assessment of neurological and psychiatric conditions without requiring clinic visits, dedicated devices, or clinical raters. Data is processed by a secure, HIPAA-compliant AI platform in real-time with results that are explainable and auditable. The platform is listed with the FDA as a Class II medical device.

Differentiator

Problem solved

Functional benefit

Brands

  • Tina: Modality's virtual guide named Tina that leads structured conversations with patients to standardize assessment across sites and languages, reduce site burden, and enable effective decentralized trials.

Products and services

  • The Modality Platform

Quantifiable outcome

  • Digital speech endpoints were sensitive to short-term disease progression in a Phase 1b ALS trial (VRG50635), detecting functional decline during the 8-week pretreatment run-in period
  • +4 more outcomes

Companies that use Modality.AI

Customer profile

Named customers8 records

Segments3 records

Ideal customer profiles2 records

Modality.AI technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature7 records

Modality.AI partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered core and minor.

  • Ametris (formerly ActiGraph)coreStrategic or Co-development Partner · 17 July 2025Strategic partnership combining Modality's sensitive speech/visual measures with Ametris's continuous real-world function data from wearable sensors. The goal is to sharpen signal detection in challenging neuro trials by enabling sponsors to better assess whether a therapy is demonstrating measurable efficacy. Joint webinars and co-presentations at ADDS (Ametris Digital Data Summit). Ametris rebranded from ActiGraph in 2025.
  • Verge GenomicscoreStrategic or Co-development Partner · 17 July 2025Modality provided speech endpoint assessments for Verge Genomics' VRG50635 Phase 1b ALS clinical trial, demonstrating that digital speech endpoints tracked disease progression and aligned with standard clinical outcomes including ALSFRS-R, respiratory function, and neurofilament biomarkers. Results published in Nature Scientific Reports.
  • Target ALScoreStrategic or Co-development PartnerTarget ALS and Modality.AI collaborate in a multimodal study of ALS, leveraging the Modality Platform for remote audiovisual assessments in the Target ALS Global Natural History Study (14 people with ALS). Joint presentations at Target ALS Annual Meeting and multiple co-authored publications.
  • EverythingALScoreStrategic or Co-development PartnerModality partners with EverythingALS on the Speech Project, generating the largest longitudinal audiovisual dataset of people with ALS (143 pALS). Collaborative research presentations and co-authored publications advancing ALS speech biomarker science.
  • Precision ALSminorStrategic or Co-development PartnerEuropean collaboration for ALS research and clinical trials, with Modality participating in Precision ALS meetings and events in Europe.
  • Nathan S. Kline Institute for Psychiatric Research (NKI)coreStrategic or Co-development PartnerLong-standing collaboration on speech and visual assessments for schizophrenia, resulting in 17+ peer-reviewed publications. Collaborators include Dr. Jean-Pierre Lindenmayer (Director of the Manhattan Schizophrenia Research Program at NKI).
  • Valis BioscienceminorStrategic or Co-development PartnerCollaboration with Valis Bioscience on CNS clinical research, with joint presence at the ASCP Annual Meeting. Valis Bioscience co-founders include Christian Yavorsky.
  • MGH Institute of Health ProfessionscoreStrategic or Co-development PartnerNIH awarded a $2.3 million grant to Modality.AI and the MGH Institute of Health Professions to validate if app-collected data is as effective as expert clinical observations for ALS diagnosis.
  • IBM T.J. Watson Research CenterminorStrategic or Co-development PartnerIBM Staff Research Scientist Kely Norel presented on deep learning models for assessing speech intelligibility in ALS, building on data collected through EverythingALS's Speech Project in collaboration with Modality.AI.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Modality.AI competitors and assessment

Company assessment

Emerging players

  • Altoida: Digital cognitive assessment platform combining AR-based motor and cognitive tasks with AI for early detection of neurological conditions. Adjacent in digital neuro assessment but more consumer/clinical than pharma-trial focused.

Broad incumbents

  • Medidata Solutions (Dassault Systèmes): Major eClinical platform serving pharma/biotech with Rave EDC, eCOA, and trial technology infrastructure. Potential incumbent competitor or partner if it expands native digital endpoint / biomarker capabilities.
  • Clario (formerly ERT): Large clinical trial technology vendor offering eCOA, imaging, respiratory, and digital endpoint solutions to pharma sponsors. Broader portfolio than Modality, but overlaps in regulated digital endpoints for clinical trials.

Direct peers

  • VivoSense: Develops and validates digital endpoints from wearable sensor data for use in regulatory-grade clinical trials. Comparable positioning as a regulated digital endpoint provider for pharma.
  • Beacon Biosignals: EEG-based digital biomarker platform for CNS clinical trials, including neurodegenerative and psychiatric indications. Overlaps with Modality on the goal of replacing subjective clinical scales with objective, regulated digital measures.
  • Sonde Health: Voice biomarker platform analyzing short voice samples for mental and respiratory health monitoring. Comparable AI-on-speech approach for health-condition detection, though more consumer- and primary-care oriented.
  • Aural Analytics: Speech analytics platform that extracts clinical-grade speech biomarkers for neurological conditions. Direct competitor in the speech-as-biomarker niche for pharma trials.
  • Cambridge Cognition: Provides digital cognitive and speech-based assessments for CNS clinical trials across indications including Alzheimer's, Parkinson's, and schizophrenia. Closely comparable to Modality in deploying validated digital endpoints for pharma-sponsored studies.
  • Cogstate: Digital cognitive testing company supplying computerized assessments (including speech/voice elements) to clinical trials across CNS indications. Comparable go-to-market selling objective digital endpoints into pharma trials.
  • Koneksa Health: Digital biomarker company deploying wearable and remote sensor data as clinical trial endpoints in CNS, respiratory, and other indications. Overlaps with Modality on objective, decentralized trial endpoints for pharma sponsors.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights8 records

Customer concentration

Modality.AI social profiles

Digital presence

Modality.AI compliance and trust

Trust signal

Compliance3 records

Modality.AI financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Modality.AI leadership team

Management profile

Number of profiles

Profiles16 records

Modality.AI funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors16 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Modality.AI M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Modality.AI

What does Modality.AI do?

Modality.AI provides an AI-powered multimodal assessment platform that uses real-time audiovisual dialog with a virtual guide named Tina to objectively evaluate speech, facial expression, and motor function in patients with neurological and psychiatric conditions. The platform enables both in-clinic and remote administration of clinical trial assessments, allowing pharma and biotech sponsors to supplement or replace rater-based endpoints with automated digital biomarkers. Data is processed in real time on a HIPAA-compliant AI platform, producing explainable, auditable results, and the platform is listed with the FDA as a Class II medical device.

Is Modality.AI a public or private company?

Modality.AI is a private company. It is classified as venture growth investor backed and is currently operating.

When was Modality.AI founded?

Modality.AI was founded in 2018. It employs 11 to 50 people.

Where is Modality.AI based?

Modality.AI is headquartered in San Francisco, United States, in the North America region.

How does Modality.AI make money?

One revenue line is on record: clinical Trial Assessment Platform (SaaS).

Who are Modality.AI's main competitors?

Altoida is listed as an emerging player. Broad incumbents are Medidata Solutions (Dassault Systèmes) and Clario (formerly ERT). Direct peers are VivoSense, Beacon Biosignals, Sonde Health, Aural Analytics, Cambridge Cognition, Cogstate and Koneksa Health.

Does Modality.AI have an API?

No public API is recorded for Modality.AI.

What industry is Modality.AI in?

Modality.AI's product category is Clinical Trial Digital Biomarker Software. Its primary akta.pro industry code is HDAAAFAC, Conversational AI Platforms (chat/voice bots, orchestration). Its NAICS code is 54151 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Pharma LetterAmprion and Modality.AI work together on biomarkers projectAmprion and Modality.AI have formed a partnership to explore the use of molecular biomarkers and AI in neurodegenerative disease research. Their collaboration aims to link evidence of disease biology with changes in speech, cognition, and behavior through Amprion's seed amplification testing and Modality.AI's Tina platform. This integration allows assessments to be conducted at clinical sites or remotely, enhancing research capabilities in this field.Business Wire BlogAmprion and Modality.AI Break New Ground in Multimodal Assessment for Neurodegenerative DiseaseAmprion and Modality.AI announced a collaboration to combine molecular biomarkers with AI-enabled digital assessments for improved characterization of neurodegenerative diseases including Parkinson's disease, dementia with Lewy bodies, MSA, and ALS. The partnership integrates Amprion's seed amplification testing technology with Modality.AI's browser-based Tina platform to provide more complete disease monitoring and patient stratification for clinical research. The collaboration aims to support therapeutic development by generating richer datasets that connect biological markers with observable disease progression.FinancialContent Business PageAmprion and Modality.AI Break New Ground in Multimodal Assessment for Neurodegenerative DiseaseAmprion and Modality.AI have announced a collaboration to combine molecular biomarkers with AI-enabled digital assessments for improved characterization of neurodegenerative diseases. The partnership integrates Amprion's seed amplification testing technology for detecting misfolded proteins with Modality.AI's Tina platform, which uses structured audiovisual conversations to generate objective measures of speech, language, facial expression, cognition, and behavior. The collaboration aims to support clinical research, improve patient stratification, and generate evidence for therapeutic development across conditions including Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, and ALS.MorningstarAmprion and Modality.AI Break New Ground in Multimodal Assessment for Neurodegenerative DiseaseAmprion and Modality.AI announced a collaboration to combine molecular biomarkers with AI-enabled digital assessments for neurodegenerative disease. The partnership aims to improve patient characterization and support clinical research, with early focus on Parkinson's disease, dementia with Lewy bodies, and related disorders. Amprion will showcase developments at the Alzheimer's Association International Conference in July 2026.GlobeNewswireVerge Genomics Will Use Modality.AI in Its ALS Phase 1b Clinical Trial of Its Lead Drug Candidate VRG50635Verge Genomics will incorporate Modality.AI's multimodal speech and language assessment into its Phase 1b trial of VRG50635, a PIKfyve inhibitor for ALS. The company expects the trial to move in the coming months, using objective speech measures to quantify changes in vocal communication.GlobeNewswireRelentless Adds AI-Powered Platform Dedicated to CNS Chronic Care Management to the PortfolioRelentless Venture Fund invested in Modality.AI, a California-based SaaS company developing an AI platform to assess neurological and psychiatric conditions. The platform uses a virtual agent to guide patients through behavioral tasks, providing objective measures of disease progression. The investment was led by an international syndicate, with Relentless partners joining the board.GlobeNewswireRelentless Adds AI-Powered Platform Dedicated to CNS Chronic Care Management to the PortfolioRelentless Venture Fund has invested in Modality.AI, a California-based B2B SaaS company that provides an AI-powered platform for assessing neurological and psychiatric conditions. The investment supports the expansion of Modality's system, which uses conversational AI to monitor chronic diseases such as schizophrenia, Parkinson’s, and autism through objective digital biomarkers.